{"filing":{"accession_number":"0001213900-26-082007","cik":"0001553643","ticker":"RLMD","company_name":"RELMADA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"ea0299449-8k_relmada.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026082007/ea0299449-8k_relmada.htm"},"events":[{"id":20943,"run_id":18864,"accession_number":"0001213900-26-082007","anchor_item_number":"7.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Bipin Dalmia, PhD, MBA as Chief Business Officer of Relmada Therapeutics, effective July 28, 2026. The press release emphasizes his nearly three decades of biopharmaceutical leadership, his expertise in NMIBC and intravesical therapies, and his direct reporting relationship to the CEO. This is a material executive appointment to a senior officer role at a clinical-stage biotechnology company.","company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","filing_date":"2026-07-28","form":"8-K","submitted_at":null,"items":[{"id":20454,"accession_number":"0001213900-26-082007","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Bipin Dalmia, PhD, MBA as Chief Business Officer of Relmada Therapeutics, effective July 28, 2026. The press release emphasizes his nearly three decades of biopharmaceutical leadership, his expertise in NMIBC and intravesical therapies, and his direct reporting relationship to the CEO. This is a material executive appointment to a senior officer role at a clinical-stage biotechnology company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T12:36:51.706474+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20454,"accession_number":"0001213900-26-082007","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Bipin Dalmia, PhD, MBA as Chief Business Officer of Relmada Therapeutics, effective July 28, 2026. The press release emphasizes his nearly three decades of biopharmaceutical leadership, his expertise in NMIBC and intravesical therapies, and his direct reporting relationship to the CEO. This is a material executive appointment to a senior officer role at a clinical-stage biotechnology company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T12:36:51.706474+00:00","company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","filing_date":"2026-07-28"}]}